Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as MK-0777
Merck L-830982 · 1 trial · 1 indication
The N-back task is a sequential-letter memory task for which working memory load is varied, as the respondent must indicate when the current stimulus matches the one from 'n' steps earlier in the sequence. The dependent measure for the N-back task was performance in the 2-back condition, which provides the best index of performance and dorsolateral prefrontal cortex disturbances in subjects with schizophrenia.
The N-back task is a sequential-letter memory task for which working memory load is varied, as the respondent must indicate when the current stimulus matches the one from 'n' steps earlier in the sequence. The dependent measure for the N-back task was performance in the 2-back condition, which provides the best index of performance and dorsolateral prefrontal cortex disturbances in subjects with schizophrenia.
For the AX Continuous Performance Test, subjects are required to maintain an attentional set across a delay interval in order to overcome a prepotent response tendency (target responses are required when an X is presented but only in the context of a preceding A; non-target conditions are AY, BX and BY). The dependent measure was d-prime at the long delay (calculated as AX hits minus BX false alarms, which is particularly sensitive to context processing impairments in individuals with schizophrenia.
The POP task is a cued stimulus-response reversal paradigm that, similar to the AX Continuous Performance Test, requires increases in cognitive control through the maintenance and use of context information to overcome prepotent response tendencies.
The POP task is a cued stimulus-response reversal paradigm that, similar to the AX Continuous Performance Test, requires increases in cognitive control through the maintenance and use of context information to overcome prepotent response tendencies.
| Arm | Type | Description |
|---|---|---|
| Merck L-830982 | EXPERIMENTAL | - |
| Sugar pill | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Merck L-830982 | DRUG | The initial dose of L-830982 was 3.0 mg twice daily (b.i.d.) the dosage increased to 5.0 mg b.i.d. at the end of week 1 and 8.0 mg b.i.d. at the end of week 2, which was continued for the remaining 2 weeks of the trial. Medications were dispensed weekly in blister packs by the hospital pharmacy. |
| Placebo | DRUG | Medications were dispensed weekly in blister packs by the hospital pharmacy, using the same number of pills as those on active drug. |
Inclusion Criteria: * Male participants * Between the ages of 18 and 50 * Meet diagnostic criteria for schizophrenia or schizoaffective disorder * Are clinically stable for a minimum of 3 months on current dose of medication * Are unemployed (i.e., work less than 20 hours per week at competitive em...
Top 15 of 16 competitors
Merck L-830982 is an investigational small molecule developed by Merck & Company, Inc. for schizophrenia. It is a Phase 2 candidate in the psychiatry therapeutic area. It has been studied in a single completed clinical trial and has not been approved for any indication.
Merck L-830982 was studied for the treatment of schizophrenia. The only recorded clinical trial of this agent enrolled adults with schizophrenia in the United States. It remains an investigational compound and is not an approved treatment for schizophrenia or any other condition.
Merck L-830982 is developed by Merck & Company, Inc., which trades on the New York Stock Exchange under the ticker MRK. The compound is an internal Merck small molecule program in psychiatry, studied for schizophrenia.
Merck L-830982 is in Phase 2 development. Its single recorded trial, NCT00129441, was a Phase 2 study that has been completed. The drug is investigational and has not received FDA approval for schizophrenia or any other indication.
Merck L-830982 has been evaluated in one clinical trial, NCT00129441, titled Gamma-Amino Butyric Acid (GABA)-A Alpha2/3 Study. That Phase 2 trial was completed, enrolled 16 participants, and was conducted in the United States in adults with schizophrenia. It was randomized, double blind, and placebo controlled.
The Phase 2 trial of Merck L-830982, NCT00129441, was a randomized, double blind, placebo controlled study in schizophrenia. It enrolled 16 participants, all male, aged 18 years and older, at sites in the United States. The study did not use biomarker-based patient selection and has been completed.